NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
14335-0471-10 | 14335-0471 | Cyclophosphamide for Injection | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 3, 2025 | In Use | |
14335-0470-10 | 14335-0470 | Cyclophosphamide for Injection | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 3, 2025 | In Use | |
14335-0472-10 | 14335-0472 | Cyclophosphamide for Injection | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 3, 2025 | In Use | |
00069-0227-03 | 00069-0227 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Jan 3, 2025 | In Use | |
50242-0079-86 | 50242-0079 | Inavolisib | Itovebi | 9.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Oral | Jan 6, 2025 | In Use | |
63323-0506-13 | 63323-0506 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Jan 6, 2025 | In Use | |
68001-0620-54 | 68001-0620 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 10, 2025 | In Use | |
72789-0401-42 | 72789-0401 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 10, 2025 | In Use | |
68071-3765-09 | 68071-3765 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jan 10, 2025 | In Use | |
24979-0726-07 | 24979-0726 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 10, 2025 | In Use | ||
24979-0726-06 | 24979-0726 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 10, 2025 | In Use | ||
70518-3922-01 | 70518-3922 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan 13, 2025 | In Use | ||
68071-3729-09 | 68071-3729 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 14, 2025 | In Use | |
50742-0354-01 | 50742-0354 | MESNA | MESNA | 400.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Oral | Jan 14, 2025 | In Use | |
60219-2281-02 | 60219-2281 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 14, 2025 | In Use | |
60219-2279-02 | 60219-2279 | Everolimus | EVEROLIMUS | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 14, 2025 | In Use | |
60219-2280-02 | 60219-2280 | Everolimus | EVEROLIMUS | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 14, 2025 | In Use | |
68071-3765-06 | 68071-3765 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jan 14, 2025 | In Use | |
83634-0801-05 | 83634-0801 | Zoledronic acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jan 15, 2025 | In Use | ||
17856-0815-01 | 17856-0815 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 15, 2025 | In Use | |
17856-0815-02 | 17856-0815 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 15, 2025 | In Use | |
17856-0815-03 | 17856-0815 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 15, 2025 | In Use | |
68001-0626-85 | 68001-0626 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Jan 17, 2025 | In Use | ||
65597-0801-01 | 65597-0801 | Datopotamab Deruxtecan | DATROWAY | 100.0 mg/5mL | Immunotherapy | Drug Antibody Conjugate | Topoisomerase I, TROP2 | Intravenous | Jan 17, 2025 | In Use | |
82249-0011-12 | 82249-0011 | Abiraterone acetate | ABIRTEGA | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral, Oral | Jan 17, 2025 | In Use |
Found 11398 results — Export these results